Matrigen Inc. was formed to develop and commercialize a cost-effective technology to combat disease process in bone and tissue and stimulate tissue regeneration. The company's products will be based on controlled-release technologies that will deliver DNA to the diseased area.
You may also be interested in...
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.
The European Commission has updated its rolling plan. It now looks as if current member state rules for non-medical products could persist beyond the 26 May 2021 deadline.